Diagnostic Histopathology
Volume 14, Issue 11 , Pages 527-537, November 2008

Pleomorphic sarcomas: subclassification, myogenic differentiation and prognosis

Louis Guillou MD is Professor of Pathology at the University Institute of Pathology, Lausanne, Switzerland

published online 06 October 2008.

Abstract 

Pleomorphic soft tissue sarcomas (STS) in adults comprise a wide range of neoplasms which can be separated into two categories: those showing myogenic differentiation (e.g. pleomorphic leiomyosarcoma and pleomorphic rhabdomyosarcoma) and those lacking this feature (e.g. myxofibrosarcoma and extraskeletal osteosarcoma). Most are high-grade, aggressive STS, although a subset belongs to the low-grade category (e.g. myxoinflammatory fibroblastic sarcoma and pleomorphic hyalinizing angiectatic tumour). Except for dedifferentiated liposarcomas, myogenic differentiation in pleomorphic sarcomas is an adverse prognostic factor, being associated with more aggressive behaviour and higher metastatic rate. Histological subtype, large size, high tumour grade, deep situation, vascular invasion, location outside the limbs and previous history of tumour recurrence(s) are additional negative prognostic indicators. This review will focus on the salient pathological, molecular and prognostic characteristics of the most common myogenic and non-myogenic pleomorphic STS.

Keywords: classification, myogenic differentiation, markers, prognosis soft tissue sarcoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 
  • * FNCLCC, French Federation of Cancer Centres.

PII: S1756-2317(08)00150-3

doi:10.1016/j.mpdhp.2008.08.002

Diagnostic Histopathology
Volume 14, Issue 11 , Pages 527-537, November 2008